Udvalget afgjorde derfor, at fordelene ved Exelon opvejer risiciene til behandling af let til middelsvær Alzheimers sygdom og let til middelsvær demens ved idiopatisk Parkinsons sygdom.
Therefore, the Committee decided that Exelon’ s benefits are greater than its risks for the treatment of mild to moderately severe Alzheimer’ s dementia and mild to moderately severe dementia in patients with idiopathic Parkinson ’ s disease.